PF4

(redirected from CXCL4)

PF4

A gene on chromosome 4q12-q21 that encodes a protein released from the alpha-granules of activated platelets which binds with high affinity to heparin. PF4’s major physiologic role appears to be neutralisation of heparin-like molecules on the endothelial surface of blood vessels, inhibiting antithrombin-III activity and promoting coagulation; as a chemoattractant for neutrophils and fibroblasts, PF4 likely plays a role in inflammation and wound repair.
References in periodicals archive ?
Expression of CXCL4 and aquaporin 3 and 10 mRNAs in patients with otitis media with effusion.
CCR5, CCR1, and CXCL4 cause fibrosis, whereas the interaction of CXCL9 and CXCR3 protects against fibrosis (21-23).
Ley, "CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages," Circulation Research, vol.
Classification Number Cytokines Panel 1 6 TNF-RII, IL19, CCL5/RANTES, MIF, MPO, Galectin-3bp Panel 2 1 IL-23 IFN/gamma, TNF/alpha, TNF/RI, GM/CSF, Panel 3 37 IL/1 beta, IL/1ra, IL1/RII, IL2, IL2 R alpha, IL4, IL5, IL6, IL6R alpha, CXCL8/ IL8, IL10, IL/15, IL17A, IL22, CCL2, CCL4, CCL7, CCL11, CCL13, CCL18, CCL22, CCL27, CXCL1/GRO alpha, CXCL4, CXCL10, CXCL12/SDF-1 alpha, CXCL13, CD14, CD27, CD30, CD40, NCAM-1/CD56, B7-H1/PD-L1/ CD274 Table 2: The outcomes of monkeys infected with M.
Gross et al., "The cathelicidin LL-37 activates human mast cells and is degraded by mast cell tryptase: counter-regulation by CXCL4," The Journal of Immunology, vol.
(2005) CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production.
As shown in Table 1, other genes followed this trend: Illb, Lectl, Procollagen type XVIII al (Coll8al), Chemokine (C-X-C motif) ligand-4 (Cxcl4), FMS-like tyrosine kinase-1 (Fltl), Interleukin-10 (1110).
van Bon and colleagues further established that CXCL4 downregulates the anti-fibrotic cytokine IFN-[gamma] and upregulates the profibrotic cytokines IL-4 and IL-13 [41].
23 December 2013 - A research team from the Boston University School of Medicine and their colleagues have discovered that levels of CXCL4 in systemic sclerosis patients may predict progression in systemic sclerosis phenotypes and that it correlates with skin and pulmonary disease.